Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Evotaz

    - PMLiVE

    Roche’s Lunsumio receives positive CHMP opinion for follicular lymphoma

    The recommendation for the subcutaneous formulation follows encouraging trial data

    - PMLiVE

    MSD receives NICE recommendation for Keytruda in advanced endometrial cancer

    More than 9,700 new cases of endometrial cancer are diagnosed every year in the UK

    EU flag

    CHMP recommends BeOne Medicines’ Tevimbra for new lung cancer indication

    Non-small cell lung cancer accounts for up to 90% of all lung cancer cases

    - PMLiVE

    Eli Lilly’s Alzheimer’s disease drug donanemab recommended by CHMP

    Up to 6.9 million people in Europe are affected by the neurodegenerative disorder

    - PMLiVE

    Moderna’s LP.8.1-adapted COVID-19 vaccine recommended by CHMP

    Global health authorities have recommended that vaccines for the 2025-2026 season should target LP.8.1

    EU flag

    CHMP recommends tablet formulation of BeOne’s targeted cancer drug Brukinsa

    The new formulation would allow blood cancer patients to halve their daily pill intake

    - PMLiVE

    Sanofi’s Sarclisa recommended by CHMP for new multiple myeloma indication

    Around 46,000 cases of the disease are expected to be diagnosed in Europe this year

    - PMLiVE

    Ipsen receives CHMP recommendation for Cabometyx in neuroendocrine tumours

    The number of patients newly diagnosed with NETs is believed to be on the rise

    - PMLiVE

    Merck’s perioperative Keytruda regimen approved by FDA for head and neck cancer

    More than 72,680 new cases of the disease are expected to be diagnosed in the US this year

    - PMLiVE

    AstraZeneca receives CHMP recommendation for Imfinzi regimen in bladder cancer

    More than 614,000 cases of bladder cancer are diagnosed globally every year

    - PMLiVE

    Merck shares promising phase 3 results for Keytruda in ovarian cancer

    Approximately 20,890 cases of the disease are expected to be diagnosed in the US this year

    - PMLiVE

    AstraZeneca’s Calquence regimens recommended by CHMP for chronic lymphocytic leukaemia

    It is hoped that the fixed-duration treatments will reduce the risk of adverse events and drug resistance

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links